Posted by Michael Wonder on 15 Dec 2021
Nuvation Bio receives FDA fast track designation for NUV-422 for the treatment of high grade gliomas, including glioblastoma multiforme
15 December 2021 - Nuvation Bio today announced that the U.S. FDA has granted fast track designation to NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, for the treatment of patients with high grade gliomas, including glioblastoma multiforme.
NUV-422 received orphan drug designation for the treatment of patients with malignant gliomas from the FDA in the first quarter of 2021.
